Investigators evaluated progression-free survival in men with high-risk prostate cancer assigned to dose-escalated radiotherapy plus long-term androgen deprivation therapy.
Between June 1997 and February 2003, stage T1b-4 prostate cancer patients were enrolled onto a multicenter randomized trial comparing 68 Gy with 78 Gy. Patients were stratified by institution, age, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results